Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics, Inc. officer Daniel Lorrain reported a proposed sale of 4,170 common shares, with an aggregate market value of $40,407.30; Morgan Stanley Smith Barney LLC Executive Financial Services is listed as broker. The notice also lists prior sales under the 10b5-1 Sales heading: 4,170 shares for $53,883.91 on October 1, 2026, and 9,520 shares for $154,895.52 on September 1, 2026.
Contineum Therapeutics, Inc. (CTNM) reported a third-quarter net loss of $18.7 million, versus $12.8 million a year earlier, with operating expenses of $21.0 million versus $14.9 million. No revenue was recognized during the three or nine months ended September 30, 2026 or 2025. Its Phase 2 PROPEL-IPF trial of PIPE-791 is underway, and management expects completion in June 2028. The FDA raised blood-pressure concerns about LPAR1 antagonists and recommended additional clinical data; the company said completed PIPE-791 trials showed no clinically relevant adverse safety signals. Janssen's Phase 2 MOONLIGHT-1 trial of PIPE-307 did not meet its primary efficacy endpoint; Janssen continues to evaluate the data.
At September 30, 2026, cash, cash equivalents and marketable securities were $244.5 million, which management expects to support operations for at least 12 months from the statements' issuance. In Q3, CTNM sold 1,409,443 shares through its at-the-market program at a weighted average price of $14.19 per share, generating $20.0 million gross and $19.4 million net proceeds. Net cash used in operations for the first nine months was $38.8 million, compared with $42.3 million in 2025.
Contineum Therapeutics, Inc. (CTNM) reported third-quarter 2026 net loss of $18.7 million, compared with $12.8 million in third-quarter 2025. Research and development expenses were $16.0 million, up 45%, primarily because of higher costs for the PIPE-791 IPF program and employee-related costs. General and administrative expenses were $5.0 million, up 26%, primarily reflecting higher stock-based compensation and employee-related costs. For the nine months ended September 30, 2026, net loss was $48.3 million, compared with $44.8 million for the same period in 2025.
Cash, cash equivalents and marketable securities totaled $244.5 million as of September 30, 2026, and Contineum believes those resources are sufficient to fund planned operations through mid-2029. The company said PROPEL-IPF, its global Phase 2 trial of once-daily oral PIPE-791 for idiopathic pulmonary fibrosis, had more than 100 sites online in 16 countries. The trial is evaluating approximately 324 patients with 26 weeks of treatment.
Contineum Therapeutics, Inc. (CTNM) is the issuer of Class A common stock for which Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each report beneficial ownership of 1,700,000 shares, or approximately 5.1%. The entries describe the same fund holdings, not four separate blocks.
The reported position comprises 1,255,000 common shares and 445,000 shares underlying long call options held by Squadron Capital Management LLC that are currently exercisable. The percentage calculation uses 32,958,632 shares outstanding as of July 24, 2026, plus the 445,000 shares issuable upon option exercise. Squadron Capital Management LLC, Matthew Sesterhenn and William Blank expressly disclaim beneficial ownership of the reported securities.
Contineum Therapeutics, Inc. (CTNM) is the issuer in an amended beneficial-ownership report showing 1,704,550 Class A common shares, or 5.2% of the class, as of September 30, 2026. The detailed ownership disclosure attributes sole voting and dispositive power over those shares to Franklin Advisers, Inc. The securities are beneficially owned by investment companies and other managed accounts that are investment-management clients; those clients have rights to dividends and sale proceeds. Franklin Resources, Inc. was renamed Franklin Templeton, Inc., effective August 17, 2026.
For Contineum Therapeutics, Inc. (CTNM), Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai, Chief Investment Officer of Trails Edge Capital, may each be deemed beneficial owners of the same 1,679,443 shares of Class A common stock, equal to 5.1% of the outstanding shares as of September 22, 2026.
Trails Edge Biotechnology Master Fund holds the shares directly. Trails Edge Capital is the fund’s investment manager, and Yehudai exercises voting and investment discretion over the shares. Each filer reports sole voting and dispositive power over 1,679,443 shares, with zero shared voting and dispositive power. The reported percentage is based on 32,958,632 shares issued and outstanding as of July 24, 2026.
Contineum Therapeutics, Inc. (CTNM) officer Daniel Lorrain reported a proposed sale of 4,170 common shares, with an aggregate market value of $55,961.40, through Morgan Stanley Smith Barney LLC; the approximate sale date is October 1, 2026. The shares are listed as acquired from the issuer as restricted stock units on May 9, 2017. The notice also lists five earlier sales under its 10b5-1 Sales heading, dated July 8 through September 1, 2026.
Contineum Therapeutics, Inc. (CTNM) reported that its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint. The study evaluated improvement from baseline in Montgomery-Åsberg Depression Rating Scale total score at Day 5 versus placebo. JNJ-5120/PIPE-307 was reported to be well tolerated with no new safety signals. Johnson & Johnson, which is developing the drug under a global license and development agreement with Contineum, is continuing to analyze the Phase 2 data, including prespecified exploratory endpoints, to assess the clinical relevance of the findings and determine potential next steps.
Contineum Therapeutics, Inc. (CTNM) reported that CEO and President Carmine N. Stengone exercised options to acquire 2,500 shares of Class A common stock on September 8, 2026 at an exercise price of $1.01 per share and sold 2,500 shares on the same day at a weighted average price of $16.4566 per share. The option was granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, is fully vested, and after this exercise 274,430 option shares from this award remain outstanding. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics, Inc. (CTNM) reports that securities associated with Carmine Stengone are being notified for potential sale under Rule 144. The notice covers a planned sale of 2,500 shares of common stock on September 8, 2026, following recent 10b5-1 sales over the prior three months.